Morgan Stanley upgraded Ionis Pharmaceuticals (IONS) to Overweight from Equal Weight with a price target of $62, up from $55. The company reported “another beat and raise” quarter on strong early launch trends for Tryngolza, the analyst tells investors in a research note. The firm now has increased conviction in Ionis’ severe hypertriglyceridemia opportunity and sees multiple catalysts ahead for the shares, beginning with the Phase 6 SHTG data in September.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals: Strong Financial Performance and Promising Prospects Justify Buy Rating
- Ionis Pharmaceuticals raises FY25 revenue view to $825M-$850M from $725M-$750M
- Ionis Pharmaceuticals reports Q2 EPS 70c, consensus 16c
- Barclays says Merck/AstraZeneca earnings neutral to Moderna, negative to Ionis
- IONS Earnings this Week: How Will it Perform?